DDInter1640 DDInter899
Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared to other antiretroviral therapies. While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%), its current indications require the co-administration of ritonavir - a potent enzyme inhibitor - that increases the bioavailability and subsequent serum concentrations of saquinavir, thus dramatically improving antiviral activity.[A214382,L3450,L14351]
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Saquinavir {u} (Compound) resembles {v} (Compound) Lopinavir
Saquinavir {u} (Compound) resembles {v} (Compound) Nelfinavir
Saquinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Saquinavir {u} (Compound) binds {v} (Gene) SLCO1B1
Saquinavir {u} (Compound) upregulates {v} (Gene) UBQLN2
Saquinavir {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A Inhibitors
Saquinavir {u} (Compound) downregulates {v} (Gene) COG2
Saquinavir {u} (Compound) causes {v} (Side Effect) Renal failure acute
Saquinavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Saquinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin human
Saquinavir (Compound) resembles Lopinavir (Compound)
Saquinavir (Compound) resembles Nelfinavir (Compound)
Saquinavir (Compound) treats acquired immunodeficiency syndrome (Disease)
Saquinavir (Compound) binds SLCO1B1 (Gene)
Saquinavir (Compound) upregulates UBQLN2 (Gene)
Saquinavir (Compound) is included by Cytochrome P450 3A Inhibitors (Pharmacologic Class)
Saquinavir (Compound) downregulates COG2 (Gene)
Saquinavir (Compound) causes Renal failure acute (Side Effect)
Saquinavir may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Insulin human